Drugs that contain Naloxone Hydrochloride; Oxycodone Hydrochloride
1. List of Targiniq drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US9522919 | PURDUE PHARMA LP | Oxycodone compositions |
Mar, 2025
(2 years from now) | |
| US9073933 | PURDUE PHARMA LP | Oxycodone hydrochloride having less than 25 PPM 14-hydroxycodeinone |
Mar, 2025
(2 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8969369 | PURDUE PHARMA LP | Abuse-resistant controlled-release opioid dosage form |
May, 2022
(8 months ago) | |
| US9161937 | PURDUE PHARMA LP | Abuse-resistant controlled-release opioid dosage form |
May, 2022
(8 months ago) | |
| US9345701 | PURDUE PHARMA LP | Abuse-resistant controlled-release opioid dosage form |
May, 2022
(8 months ago) | |
| US9084729 | PURDUE PHARMA LP | Abuse-resistant controlled-release opioid dosage form |
May, 2022
(8 months ago) | |
| US9283216 | PURDUE PHARMA LP | Abuse-resistant controlled-release opioid dosage form |
May, 2022
(8 months ago) | |
| US9056051 | PURDUE PHARMA LP | Abuse-resistant controlled-release opioid dosage form |
May, 2022
(8 months ago) | |
| US9283221 | PURDUE PHARMA LP | Abuse-resistant controlled-release opioid dosage form |
May, 2022
(8 months ago) | |
| US9168252 | PURDUE PHARMA LP | Abuse-resistant controlled-release opioid dosage form |
May, 2022
(8 months ago) | |
| US9511066 | PURDUE PHARMA LP | Abuse-resistant controlled-release opioid dosage form |
May, 2022
(8 months ago) | |
| US8846090 | PURDUE PHARMA LP | Matrix for sustained, invariant and independent release of active compounds |
Apr, 2023
(a month from now) | |
| US9555000 | PURDUE PHARMA LP | Pharmaceutical preparation containing oxycodone and naloxone |
Apr, 2023
(a month from now) | |
| US9907793 | PURDUE PHARMA LP | Pharmaceutical preparation containing oxycodone and naloxone |
Apr, 2023
(a month from now) | |
| US8846091 | PURDUE PHARMA LP | Matrix for sustained, invariant and independent release of active compounds |
Apr, 2023
(a month from now) | |
Market Authorisation Date: 23 July, 2014
Treatment: Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate; Management of pain severe enough to require daily, around-the-clock, long term opioid treatment and for which alternative treatment options are inadequate; Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate by providing an abuse-deterrent oral controlled release combination drug product
Dosage: TABLET, EXTENDED RELEASE;ORAL
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic